Revolution Medicines shares promising data around KRAS drug combination
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Revolution Medicines shares promising data around KRAS drug combination" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Oncodaily, Medscape, Yahoo Finance and WSAW. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 95d ago.
Quick answers
Why is "Revolution Medicines shares promising data around KRAS drug combination" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Anirban Maitra։ Data on Zoldonrasib Plus Daraxonrasib in 2nd and 3rd Line Metastatic Pancreatic Cancer Oncodaily · 98d ago
- Practice-Changing Data in GI Oncology Medscape · 98d ago
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Yahoo Finance · 98d ago
- Experimental cancer drug brings time and hope for patients WSAW · 98d ago
- Revolution Medicines shares promising data around KRAS drug combination Endpoints News · 98d ago
Topics
Related trends
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
Pancreatic Cancer Disappears in Mice After New mRNA Immunotherapy
Recent studies detail an mRNA immunotherapy strategy that reportedly leads to pancreatic cancer disappearing in mice.
Lab-Grown Meat: A Revolution Fizzles
The lab-grown meat industry faces a critical turning point as initial excitement gives way to regulatory warnings and a strategic shift toward integration.
The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
New pancreatic cancer drug that doubled survival time now reaching Charleston patients
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
How Brentford FC’s Data Revolution Turned the Premier League Upside Down
5 news sources are covering this Sports story right now — PULSE is tracking how fast it spreads.